Hansoh Biomedical R&d Company

This early-stage study is testing the safety and side effects of a new two-drug combination for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The trial combines an antibody-drug (HS-20093) that targets cancer cells with a second drug (…

This is an early-stage study to test the safety and side effects of a new drug called HS-20110 in adults with advanced solid tumors. Researchers will give the drug to participants and closely monitor how their bodies handle it and if it shows any signs of shrinking their tumors. …

This study is testing whether a new drug called HS-20089 works better than standard chemotherapy for women with ovarian cancer that has returned and stopped responding to platinum-based drugs. About 468 participants will be randomly assigned to receive either the experimental dru…

This is the first human study of a new drug called HS-20122 for people with advanced solid tumors that have stopped responding to standard treatments. Researchers will test different doses to find the safest amount and see how the drug moves through the body. The study will also …

This is an early-stage study testing a new drug called HS-20093 for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink …

This early-stage study aims to understand how a common antifungal drug (itraconazole) affects the way the body processes a new experimental cancer drug (HS-20093). It involves 18 adults with advanced solid tumors who have no other standard treatment options. The main goal is to m…